SEC Form 4 · accession 0001209191-18-030694
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly J Popovits
Officer — President and CEO · Director
Period of report
May 14, 2018
Accepted (ET)
May 16, 2018 · 6:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 14, 2018 | M | 5,000 | $17.18 | A | 241,157 | I | Held by the Popovits 2010 Trust |
| Common Stock | May 14, 2018 | M | 5,000 | $17.18 | A | 246,157 | I | Held by the Popovits 2010 Trust |
| Common StockF1,F2,F3 | May 14, 2018 | S | 5,000 | $38.0841 | D | 241,157 | I | Held by the Popovits 2010 Trust |
| Common StockF1,F2,F4 | May 14, 2018 | S | 5,000 | $38.0913 | D | 236,157 | I | Held by the Popovits 2010 Trust |
| Common StockF5 | holding | — | — | — | 59,617 | D | ||
| Common Stock | holding | — | — | — | 12,298 | I | Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits | |
| Common Stock | holding | — | — | — | 16,825 | I | Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F6 | $17.18 | May 14, 2018 | M | 5,000 | D | — | Feb 18, 2020 | Common Stock | 0 | 72,900 | D |
| Employee Stock Option (right to buy)F6 | $17.18 | May 14, 2018 | M | 5,000 | D | — | Feb 18, 2020 | Common Stock | 0 | 67,900 | D |
Explanation of responses
- F1These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 6, 2017.
- F2Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F3Represents weighted average sale price. Actual sale prices ranged from $37.60 to $38.51.
- F4Represents weighted average sale price. Actual sale prices ranged from $37.585 to $38.50.
- F5Includes an aggregate of 51,204 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F6The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.